Guidance for 2025
The following guidance assumes foreign exchange rates effective as of December 31, 2024, for the full year. Enterprise level guidance includes the estimated impact from currently anticipated capital allocation, including acquisitions, share repurchases and dividends.
| (Dollars in billions, except per share data) | ||||
| Results | 2025 Guidance | |||
| 2024 | Low | High | ||
| Revenue | ||||
| Labcorp Enterprise (1)(2) | $13.01 | 6.7 % | 8.0 % | |
| Diagnostics Laboratories (3) | $10.14 | 6.5 % | 7.7 % | |
| Biopharma Laboratory Services (4) | $2.92 | 3.0 % | 5.0 % | |
| Adjusted EPS | $14.57 | $15.60 | $16.40 | |
| Free Cash Flow | $1.10 | $1.10 | $1.25 | |
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.